⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ESPR News
Esperion Therapeutics, Inc.
Esperion to Report First Quarter 2026 Financial Results on May 7
globenewswire.com
ESPR
Espresa Launches Specialty Care Accounts to Give Employers Predictable Control Over Rising Costs of Popular Drugs Such as GLP-1s
accessnewswire.com
ESPR
Form 8-K
sec.gov
ESPR
Athyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing to Support Strategic Acquisition of Corstasis Therapeutics
globenewswire.com
ESPR
Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)
globenewswire.com
ESPR
Esperion to Participate in 25th Annual Needham Virtual Healthcare Conference
globenewswire.com
ESPR
Esperion Showcases New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) at the American College of Cardiology’s Annual Scientific Session 2026
globenewswire.com
ESPR
Esperion to Present Two New Analyses from CLEAR Outcomes Clinical Trial at the American College of Cardiology 2026 Annual Scientific Session
globenewswire.com
ESPR
Esperion’s Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia
globenewswire.com
ESPR
Form 8-K
sec.gov
ESPR